Toxicity of abortifacients: A review for physicians in the post roe era
On June 24, 2022, the Supreme Court overturned Roe v. Wade, which will limit legal abortion in many areas of the U.S. Over half of abortions in the U.S. are performed using medication as opposed to surgical techniques. With widespread access to agents that are used for medication abortion, there may...
Gespeichert in:
Veröffentlicht in: | The American journal of emergency medicine 2022-11, Vol.61, p.7-11 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 11 |
---|---|
container_issue | |
container_start_page | 7 |
container_title | The American journal of emergency medicine |
container_volume | 61 |
creator | Mazer-Amirshahi, Maryann Ye, Peggy |
description | On June 24, 2022, the Supreme Court overturned Roe v. Wade, which will limit legal abortion in many areas of the U.S. Over half of abortions in the U.S. are performed using medication as opposed to surgical techniques. With widespread access to agents that are used for medication abortion, there may be an increase in emergency department presentations related to improper or unsupervised use of these medications.
This narrative review focuses on the contraindications, adverse effects, and toxicities of the most common agents used for medication abortion in the U.S.
Medications included in this review are mifepristone, misoprostol, and methotrexate. Each of these medications has a unique adverse effect and toxicity profile.
Agents used for medication abortion have unique contraindications and adverse effects. Improper or unsupervised use may occur in the setting of limited abortion access and emergency medicine physicians are on the front lines in managing these presentations.
•Medication abortion accounts for the majority of abortions performed in the U.S.•Restricted abortion access may lead to improper use of these medications.•Medications used for abortion have unique adverse effects and toxicities.•Emergency physicians should be prepared to manage women presenting with toxicity. |
doi_str_mv | 10.1016/j.ajem.2022.08.027 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2725607999</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0735675722005289</els_id><sourcerecordid>2725607999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c384t-204353894102a2cc93e205d252def1e98594254042aa5dc66d9d557ff13adc4a3</originalsourceid><addsrcrecordid>eNp9kEFPGzEQhS1UBCnwBzggSz3vMh7b613EJUKQVorEBc6WsWeFVyQO9qZt_n03StpjT3P53nuaj7FrAbUA0dwOtRtoVSMg1tDWgOaEzYSWWLXCiC9sBkbqqjHanLOvpQwAQiitzti5bACMkjhji5f0O_o47njquXtLeYy985HWY7njc57pZ6RfvE-Zb953ZSLduvC45uM78U0qI8-JOGV3yU5791Ho6ngv2OvT48vD92r5vPjxMF9WXrZqrBCU1LLtlAB06H0nCUEH1BioF9S1ulOoFSh0TgffNKELWpu-F9IFr5y8YN8OvZucPrdURjukbV5PkxYN6gZM13UThQfK51RKpt5ucly5vLMC7N6dHezend27s9Dayd0UujlWb99WFP5F_sqagPsDQNODk5dsy96UpxAz-dGGFP_X_wcjJ34y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2725607999</pqid></control><display><type>article</type><title>Toxicity of abortifacients: A review for physicians in the post roe era</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Mazer-Amirshahi, Maryann ; Ye, Peggy</creator><creatorcontrib>Mazer-Amirshahi, Maryann ; Ye, Peggy</creatorcontrib><description>On June 24, 2022, the Supreme Court overturned Roe v. Wade, which will limit legal abortion in many areas of the U.S. Over half of abortions in the U.S. are performed using medication as opposed to surgical techniques. With widespread access to agents that are used for medication abortion, there may be an increase in emergency department presentations related to improper or unsupervised use of these medications.
This narrative review focuses on the contraindications, adverse effects, and toxicities of the most common agents used for medication abortion in the U.S.
Medications included in this review are mifepristone, misoprostol, and methotrexate. Each of these medications has a unique adverse effect and toxicity profile.
Agents used for medication abortion have unique contraindications and adverse effects. Improper or unsupervised use may occur in the setting of limited abortion access and emergency medicine physicians are on the front lines in managing these presentations.
•Medication abortion accounts for the majority of abortions performed in the U.S.•Restricted abortion access may lead to improper use of these medications.•Medications used for abortion have unique adverse effects and toxicities.•Emergency physicians should be prepared to manage women presenting with toxicity.</description><identifier>ISSN: 0735-6757</identifier><identifier>EISSN: 1532-8171</identifier><identifier>DOI: 10.1016/j.ajem.2022.08.027</identifier><identifier>PMID: 36007432</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Abortifacient Agents - adverse effects ; Abortion ; Abortion, Induced ; Contraindications ; Counterfeiting ; Drug dosages ; Drugs ; Emergency department ; Emergency medical care ; FDA approval ; Female ; Humans ; Medication abortion ; Methotrexate ; Mifepristone ; Mifepristone - adverse effects ; Misoprostol ; Misoprostol - adverse effects ; Patients ; Physicians ; Pregnancy ; Pregnancy complications ; Side effects ; State laws ; Steroids ; Toxicity ; United States ; Vagina ; Womens health</subject><ispartof>The American journal of emergency medicine, 2022-11, Vol.61, p.7-11</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><rights>2022. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c384t-204353894102a2cc93e205d252def1e98594254042aa5dc66d9d557ff13adc4a3</citedby><cites>FETCH-LOGICAL-c384t-204353894102a2cc93e205d252def1e98594254042aa5dc66d9d557ff13adc4a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2725607999?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36007432$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mazer-Amirshahi, Maryann</creatorcontrib><creatorcontrib>Ye, Peggy</creatorcontrib><title>Toxicity of abortifacients: A review for physicians in the post roe era</title><title>The American journal of emergency medicine</title><addtitle>Am J Emerg Med</addtitle><description>On June 24, 2022, the Supreme Court overturned Roe v. Wade, which will limit legal abortion in many areas of the U.S. Over half of abortions in the U.S. are performed using medication as opposed to surgical techniques. With widespread access to agents that are used for medication abortion, there may be an increase in emergency department presentations related to improper or unsupervised use of these medications.
This narrative review focuses on the contraindications, adverse effects, and toxicities of the most common agents used for medication abortion in the U.S.
Medications included in this review are mifepristone, misoprostol, and methotrexate. Each of these medications has a unique adverse effect and toxicity profile.
Agents used for medication abortion have unique contraindications and adverse effects. Improper or unsupervised use may occur in the setting of limited abortion access and emergency medicine physicians are on the front lines in managing these presentations.
•Medication abortion accounts for the majority of abortions performed in the U.S.•Restricted abortion access may lead to improper use of these medications.•Medications used for abortion have unique adverse effects and toxicities.•Emergency physicians should be prepared to manage women presenting with toxicity.</description><subject>Abortifacient Agents - adverse effects</subject><subject>Abortion</subject><subject>Abortion, Induced</subject><subject>Contraindications</subject><subject>Counterfeiting</subject><subject>Drug dosages</subject><subject>Drugs</subject><subject>Emergency department</subject><subject>Emergency medical care</subject><subject>FDA approval</subject><subject>Female</subject><subject>Humans</subject><subject>Medication abortion</subject><subject>Methotrexate</subject><subject>Mifepristone</subject><subject>Mifepristone - adverse effects</subject><subject>Misoprostol</subject><subject>Misoprostol - adverse effects</subject><subject>Patients</subject><subject>Physicians</subject><subject>Pregnancy</subject><subject>Pregnancy complications</subject><subject>Side effects</subject><subject>State laws</subject><subject>Steroids</subject><subject>Toxicity</subject><subject>United States</subject><subject>Vagina</subject><subject>Womens health</subject><issn>0735-6757</issn><issn>1532-8171</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kEFPGzEQhS1UBCnwBzggSz3vMh7b613EJUKQVorEBc6WsWeFVyQO9qZt_n03StpjT3P53nuaj7FrAbUA0dwOtRtoVSMg1tDWgOaEzYSWWLXCiC9sBkbqqjHanLOvpQwAQiitzti5bACMkjhji5f0O_o47njquXtLeYy985HWY7njc57pZ6RfvE-Zb953ZSLduvC45uM78U0qI8-JOGV3yU5791Ho6ngv2OvT48vD92r5vPjxMF9WXrZqrBCU1LLtlAB06H0nCUEH1BioF9S1ulOoFSh0TgffNKELWpu-F9IFr5y8YN8OvZucPrdURjukbV5PkxYN6gZM13UThQfK51RKpt5ucly5vLMC7N6dHezend27s9Dayd0UujlWb99WFP5F_sqagPsDQNODk5dsy96UpxAz-dGGFP_X_wcjJ34y</recordid><startdate>202211</startdate><enddate>202211</enddate><creator>Mazer-Amirshahi, Maryann</creator><creator>Ye, Peggy</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>202211</creationdate><title>Toxicity of abortifacients: A review for physicians in the post roe era</title><author>Mazer-Amirshahi, Maryann ; Ye, Peggy</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c384t-204353894102a2cc93e205d252def1e98594254042aa5dc66d9d557ff13adc4a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abortifacient Agents - adverse effects</topic><topic>Abortion</topic><topic>Abortion, Induced</topic><topic>Contraindications</topic><topic>Counterfeiting</topic><topic>Drug dosages</topic><topic>Drugs</topic><topic>Emergency department</topic><topic>Emergency medical care</topic><topic>FDA approval</topic><topic>Female</topic><topic>Humans</topic><topic>Medication abortion</topic><topic>Methotrexate</topic><topic>Mifepristone</topic><topic>Mifepristone - adverse effects</topic><topic>Misoprostol</topic><topic>Misoprostol - adverse effects</topic><topic>Patients</topic><topic>Physicians</topic><topic>Pregnancy</topic><topic>Pregnancy complications</topic><topic>Side effects</topic><topic>State laws</topic><topic>Steroids</topic><topic>Toxicity</topic><topic>United States</topic><topic>Vagina</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mazer-Amirshahi, Maryann</creatorcontrib><creatorcontrib>Ye, Peggy</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>The American journal of emergency medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mazer-Amirshahi, Maryann</au><au>Ye, Peggy</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Toxicity of abortifacients: A review for physicians in the post roe era</atitle><jtitle>The American journal of emergency medicine</jtitle><addtitle>Am J Emerg Med</addtitle><date>2022-11</date><risdate>2022</risdate><volume>61</volume><spage>7</spage><epage>11</epage><pages>7-11</pages><issn>0735-6757</issn><eissn>1532-8171</eissn><abstract>On June 24, 2022, the Supreme Court overturned Roe v. Wade, which will limit legal abortion in many areas of the U.S. Over half of abortions in the U.S. are performed using medication as opposed to surgical techniques. With widespread access to agents that are used for medication abortion, there may be an increase in emergency department presentations related to improper or unsupervised use of these medications.
This narrative review focuses on the contraindications, adverse effects, and toxicities of the most common agents used for medication abortion in the U.S.
Medications included in this review are mifepristone, misoprostol, and methotrexate. Each of these medications has a unique adverse effect and toxicity profile.
Agents used for medication abortion have unique contraindications and adverse effects. Improper or unsupervised use may occur in the setting of limited abortion access and emergency medicine physicians are on the front lines in managing these presentations.
•Medication abortion accounts for the majority of abortions performed in the U.S.•Restricted abortion access may lead to improper use of these medications.•Medications used for abortion have unique adverse effects and toxicities.•Emergency physicians should be prepared to manage women presenting with toxicity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36007432</pmid><doi>10.1016/j.ajem.2022.08.027</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0735-6757 |
ispartof | The American journal of emergency medicine, 2022-11, Vol.61, p.7-11 |
issn | 0735-6757 1532-8171 |
language | eng |
recordid | cdi_proquest_journals_2725607999 |
source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
subjects | Abortifacient Agents - adverse effects Abortion Abortion, Induced Contraindications Counterfeiting Drug dosages Drugs Emergency department Emergency medical care FDA approval Female Humans Medication abortion Methotrexate Mifepristone Mifepristone - adverse effects Misoprostol Misoprostol - adverse effects Patients Physicians Pregnancy Pregnancy complications Side effects State laws Steroids Toxicity United States Vagina Womens health |
title | Toxicity of abortifacients: A review for physicians in the post roe era |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A51%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Toxicity%20of%20abortifacients:%20A%20review%20for%20physicians%20in%20the%20post%20roe%20era&rft.jtitle=The%20American%20journal%20of%20emergency%20medicine&rft.au=Mazer-Amirshahi,%20Maryann&rft.date=2022-11&rft.volume=61&rft.spage=7&rft.epage=11&rft.pages=7-11&rft.issn=0735-6757&rft.eissn=1532-8171&rft_id=info:doi/10.1016/j.ajem.2022.08.027&rft_dat=%3Cproquest_cross%3E2725607999%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2725607999&rft_id=info:pmid/36007432&rft_els_id=S0735675722005289&rfr_iscdi=true |